Market for psoriasis drugs will reach $11.4bn in 2020, according to new visiongain data

05 September 2018
Pharma

The updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of drugs for the treatment of psoriasis. The analysis shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of leading companies providing those medicines, assessing their potentials from 2016.

In 2015 biological drugs formed dominant source of revenue for manufacturers, accounting for 78.5% of the global drug market for psoriasis. However that segment will decline in market share over the forecast period as leading products such as AbbVie’s Humira (adalimumab), Amgen/Pfizer’s Enbrel (etanercept) and J&J/Merck’s Remicade (infliximab) face strong competition from lower-cost biosimilars and new biologics.

Alastair McDougall, a pharmaceutical industry analyst in visiongain, said: “The psoriasis drugs market is dynamic, with a lot of new products reaching the marketplace in the next few years. Many of the current biologics are coming off-patent, new biologics with novel mechanisms of action are being launched, and a lot of companies are actively developing biosimilars. Competition in the biologics sector will be fierce, and efficacy, safety and price will all be key considerations when evaluating products.”

Visiongain’s investigation shows revenue predictions at overall world market, submarket, product and national level. The report’s overarching analysis gives revenue forecasts to 2026 for three submarkets at world level:

• Biologics
• Systemic small molecule treatments
• Topical therapies.

The study also forecasts revenues of established brands and medicines expected from 2016. That work assesses 13 drugs to 2026, including these brands:

• Humira (adalimumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Stelara (ustekinumab)
• Otezla (apremilast)
• Cosentyx (secukinumab).

The analysis also covers prominent national markets for psoriasis drug sales, with revenue forecasts to 2026 for these 11 countries:

• USA
• Japan
• Germany, France, Italy, Spain and UK (the EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Visiongain’s survey examines leading pharmaceutical companies in that market. That work discusses mergers and acquisitions, collaborations and R&D for organisations including AbbVie, Amgen, Johnson & Johnson, Pfizer, Celgene, LEO Pharma and Novartis.

Psoriasis Drugs Market Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services.

Recent News

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021

Read

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever